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Abstract
Background
Perinatal or mother-to-child transmission of hepatitis B virus (HBV) results in a high frequen-
cy of chronic infection. Risk of mother-to-child transmission is associated with maternal viral
factors including hepatitis B e antigen (HBeAg) positivity and viral load.
Aim
To investigate associations between age, HBeAg status, HBV DNA levels and genotype in
female patients screened for inclusion into two contemporary, randomized HBV trials.
Methods
Retrospective analyses focused on differences between women of childbearing age
(44 years) and older women. Female patients (N = 355; 18–69 years) were included in
the analysis: 41.7% of patients were Asian. In total, 44.4% were HBeAg-positive.
Results
Significantly more women aged44 years were HBeAg-positive compared to women45
years (57.2% versus 27.5%, respectively, p<0.0001), this proportion declined with increas-
ing age. Younger women were significantly more likely to have high HBV viral load (HBV
DNA>108 copies mL:44 years 46.0% vs45 years 25.5%, respectively; p<0.0001), and
this declined with increasing age. HBeAg positivity was slightly higher in Asian women, as-
sociated with a higher proportion of HBV genotypes B and C in this population. There was
no obvious relationship between genotype and viral load.
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Conclusions
Women of childbearing age with CHB are more likely to have high HBV viral load and
HBeAg positivity than older women; this likelihood decreases with age. Maternal serological
and virological status should therefore be established early in pregnancy, taking into ac-
count age and genotype, and a risk-reducing strategy implemented in any patient who is
HBeAg positive and has a high viral load.
Introduction
Recent estimates from the World Health Organization indicate that more than 240 million
people are chronically infected with hepatitis B virus (HBV), and therefore at risk of serious
liver disease, including cirrhosis and hepatocellular carcinoma [1]. The likelihood of develop-
ing chronic HBV infection (CHB) depends on age at the time of infection: 80–90% of infants
infected during the first year of life and 30–50% of those aged 5 years and under will develop
chronic infections compared with fewer than 5% of otherwise healthy adults [1]. Perinatal or
mother-to-child transmission (MTCT) results in a high frequency of CHB, especially in highly
endemic areas where HBV is still most commonly spread from mother to child. Even in areas
of low HBV endemicity, more than a third of CHB cases have been attributed to MTCT or
early childhood transmission [1].
Several factors have been identified as increasing the risk of MTCT including maternal hep-
atitis B e antigen (HBeAg) status. HBeAg positivity in women of childbearing-age is a risk fac-
tor for intrauterine infection [2] and, consequently, a major determinant of MTCT [3–5]. The
precise mechanisms behind the high rate of infectivity in infants born to HBeAg-positive
mothers remain unclear, but may be related to the fact that maternal HBeAg positivity is
strongly correlated with high levels of maternal viremia [5–7]. Together with maternal HBeAg
positivity, HBV DNA level is an important, if not the most important, predictor and risk factor
for MTCT [8–10].
Immunoprophylaxis (both active and passive immunization) against HBV is the mainstay
of disease prevention. However, although adoption of standard immunoprophylaxis has re-
duced the rate of MTCT, up to 8–39% of infants born to highly viremic (defined as HBV
DNA>106–108 copies/mL, depending on study) HBeAg-positive mothers still become in-
fected with HBV [5,7,10–14]. High levels of maternal HBV DNA have also been associated
with failure of neonatal HBV vaccination (so-called breakthrough infection) and passive-active
immunoprophylaxis in infants of HBeAg-positive mothers [2,7,8].
The aim of our study was to investigate the associations between age, HBeAg status, HBV
DNA levels and genotype in female patients screened for inclusion into two contemporary
large randomized clinical HBV trials, focusing on differences between women of childbearing
age (44 years) and older women (45 years). The data from our study contribute to under-
standing of the natural history of CHB in women of different ages, and have clinical implica-
tions for risk-reduction strategies in pregnancy.
Materials and Methods
Study design
This was a retrospective analysis of data from female patients screened for inclusion in one of
two phase III studies of tenofovir disoproxil fumarate (TDF) versus adefovir for CHB, that
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were conducted at 106 clinical sites in 15 countries across North America (USA and Canada),
Europe (Bulgaria, Czech Republic, France, Germany, Greece, Italy, Poland, Spain, The Nether-
lands, Turkey, and UK) and the Asia-Pacific region (Australia and New Zealand).
Patients aged 18–69 years were recruited fromMay 2005 through to June 2006. Inclusion
criteria, the details of which have been previously described [15], included HBeAg-negative sta-
tus (Study 102; NCT00117676) or HBeAg-positive status (Study 103; NCT00116805) CHB
with compensated liver disease together with the presence of hepatitis B surface antigen
(HBsAg) for at least 6 months before screening. All screened female patients were included in
the current analysis, including those who did not satisfy inclusion criteria for inclusion in the
clinical trials. ‘Women of childbearing age’ were defined as those aged between 18 and 44 years
(lower limit based on the study inclusion criteria; upper limit based on Centers for Disease
Control criteria).
At screening, patients were assessed for the presence of HBeAg, level of circulating HBV
DNA and alanine aminotransferase (ALT). HBV DNA was measured using the Roche Cobas
Taq-Man polymerase-chain-reaction assay, which has a lower limit of quantitation of 169 cop-
ies/mL (29 IU/mL) [15]. The screening assessment also included a complete physical examina-
tion and measurement of vital signs. Genotype was assessed from serum samples collected at
the baseline visit. Thus, genotypic information was not available for screen failures.
Ethics statement
The original study from which data were taken was conducted in accordance with international
scientific and ethical standards, including but not limited to the International Conference on
Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki. The
study was approved by independent ethics committees or institutional review boards at the
study sites. Written informed consent was obtained from all patients before any procedures
were performed.
Statistical analyses
Standard descriptive statistics including mean, median and standard deviation were used to
summarize continuous baseline and demographic information; frequency and percentage were
used to summarize categorical variables. Comparisons between groups were done via a Wil-
coxon Rank Sum test for continuous variables and Fisher’s exact test for categorical variables.
Univariate logistic regressions were used to analyze the association between age group and
HBeAg status, HBV DNA levels, genotype and race, with age group dichotomized at various
levels ( 24, 25–34, 35–44, and 45 years), HBV DNA dichotomized at various levels (> 106,
> 107> 108> 109 copies/mL), race dichotomized as Asian versus non-Asian. Odds ratios and
95% confidence intervals from these logistic regression models are presented. Associations be-
tween HBV genotype and viral load were examined using Fisher’s exact test.
Results
Patients
A total of 355 female patients with CHB, of which 197 were HBeAg-negative and 157 HBeAg-
positive, were screened for inclusion into the two trials; HBeAg status was unknown in one in-
dividual. Overall, 202 patients (56.9%) were aged44 years and were therefore defined as
women of childbearing age. Demographic and baseline characteristics of the study population
are shown in Table 1.
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Table 1. Demographic and baseline characteristics.
Age 44 years Age 45 years Overall p-value
(n = 202) (n = 153) (n = 355)
Mean (SD) age, years 31.4 (7.72) 53.4 (5.05) 40.8 (12.81) <0.0001
Race, n (%) 0.6644
Asian 82 (40.6) 66 (43.1) 148 (41.7)
Non-Asian 120 (59.4) 87 (56.9) 207 (58.3)
Geographic region, n (%) 0.3126
Europe 120 (59.4) 79 (51.6) 199 (56.1)
North America 56 (27.7) 48 (31.4) 104 (29.3)
Australia/New Zealand 26 (12.9) 26 (17.0) 52 (14.6)
HBeAg, n (%) <0.0001
HBeAg-positive 115 (57.2) 42 (27.5) 157 (44.4)
HBeAg-negative 86 (42.8) 111 (72.5) 197 (55.6)
Unknown 1 1
Knodell necroinflammatory score* 0.0903
n 80 65 145
Mean (SD) 8.0 (2.18) 8.5 (1.77) 8.2 (2.02)
Knodell fibrosis score, n (%)* 0.0002
0 0 1 (1.5) 1 (0.7)
1 42 (52.5) 17 (26.2) 59 (40.7)
2 0 0 0
3 34 (42.5) 31 (47.7) 65 (44.8)
4 4 (5.0) 16 (24.6) 20 (13.8)
Missing 122 88 210
Mean (SD) HBV DNA, log10 copies/mL 7.3 (1.91) 6.7 (1.67) 7.0 (1.83) 0.0002
HBV DNA, copies/mL, n (%)
>106 146 (72.3) 99 (64.7) 245 (69.0) 0.1334
>107 126 (62.4) 66 (43.1) 192 (54.1) 0.0004
>108 93 (46.0) 39 (25.5) 132 (37.2) 0.0001
>109 42 (20.8) 8 (5.2) 50 (14.1) <0.0001
Mean HBsAg, IU/mL <0.001
n 99 68 167
Mean (SD) 4.2 (0.60) 3.7 (0.62) 4.0 (0.65)
Median ALT, U/L (range) 69 (8, 627) 69 (16, 806) 69 (8, 806) 0.8375
HBV genotype, n (%) 0.9252
A 14 (14.0) 7 (10.4) 21 (12.6)
B 13 (13.0) 8 (11.9) 21 (12.6)
C 23 (23.0) 16 (23.9) 39 (23.4)
D 47 (47.0) 35 (52.2) 82 (49.1)
E, F, G, H 3 (3.0) 1 (1.5) 4 (2.4)
Unknown* 102 86 188
*Biopsy, HBsAg and genotype were not available for screening failures. ALT, alanine aminotransferase; HBV DNA, hepatitis B viral DNA; HBeAg,
hepatitis B e antigen; HBsAg, hepatitis B surface antigen; SD, standard deviation
doi:10.1371/journal.pone.0121632.t001
Hepatitis B Virus Levels in Women of Childbearing Age
PLOSONE | DOI:10.1371/journal.pone.0121632 March 19, 2015 4 / 11
Associations between age, HBeAg status, HBV DNA levels and genotype
A comparison of patients in the44 years and45 years cohorts showed that women in the
younger cohort were significantly more likely to be HBeAg-positive (p<0.0001) and to have sig-
nificantly higher mean HBVDNA levels (p = 0.0002) than those aged45 years (Table 1). In ad-
dition, a significantly higher proportion of patients44 years had high HBVDNA levels
compared with the older cohort (p<0.0001 for both>108 copies/mL and>109 copies/mL HBV
DNA cut offs). There were no significant differences between groups with regards to median
ALT levels or in genotype distribution. On multivariate analysis, both HBV DNA>109 copies/
mL and HBeAg positivity were significantly associated with age44 years (odds ratio (OR) 2.59;
95% confidence interval, 1.12–6.03; p = 0.0267 and OR 2.89; 1.78–4.69; p<0.0001, respectively).
When divided into four age cohorts (24 years, 25–34 years, 35–44 years and45 years), a
greater number of younger patients were found to be HBeAg-positive than older patients
(Fig. 1). In addition, patients in the younger cohorts (44 years) tended to have higher viral
loads than older patients, with the highest proportion of patients with HBV DNA levels>108
or>109 copies/mL being in the24 years subgroup (Table 2). The proportion of women who
were both HBeAg-positive and who also had a high viral load (and therefore were at highest
risk of MTCT) was greater in the subgroups of women aged44 years than in the group of
women aged45 years. In the44 years subgroups, the proportion of HBeAg-positive
women with high HBV DNA levels using a range of cut-offs was consistently higher in high
risk women24 years of age, with the proportion falling with increasing age (Table 3).
Comparisons between patients of Asian and non-Asian ethnicity showed that ethnic origin
had an influence on HBeAg status with rates of positivity slightly higher in Asian women
(Table 4). Consistent with observations in the total study population, younger Asian and non-
Asian patients were more likely to be HBeAg positive and have high viral loads than their cor-
responding older cohorts (Table 4).
Fig 1. HBeAg status in the four age cohorts.
doi:10.1371/journal.pone.0121632.g001
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Most patients were infected with genotypes C and D (Table 1). Of those Asian patients with
available data (n = 62), with the predominant infections were genotype B (32.3%) and C
(56.5%), with few Asian patients infected with genotypes A (4.8%) or D (6.5%). Of non-Asian
women with available data (n = 105), the majority were infected with genotypes A (17.1%) and
D (74.3%), with few patients having genotype B (1.0%) or C (3.8%) infection (genotypes other
than A, B, C or D: 3.8%). Further analysis showed that a higher proportion of genotype B and
C infected women (the pattern seen in Asian women) were HBeAg-positive compared with
Table 2. HBV viral load in relation to age*.
HBV DNA levels, copies/mL, n
(%)
Age 24
years
Age 25–34
years
Age 35–44
years
Age 45
years
(n = 46) (n = 82) (n = 74) (n = 153)
>106 38 (82.6) 58 (70.7) 50 (67.6) 99 (64.7)
OR (95% CI) 2.59 1.32 1.14 —
(1.13, 5.95) (0.74, 2.35) (0.63, 2.05)
>107 36 (78.3) 51 (62.2) 39 (52.7) 66 (43.1)
OR (95% CI) 4.75 2.17 1.47 —
(2.20, 10.25) (1.25, 3.76) (0.84, 2.56)
>108 31 (67.4) 40 (48.8) 22 (29.7) 39 (25.5)
OR (95% CI) 6.04 2.78 1.24 —
(2.95, 12.36) (1.58, 4.90) (0.67, 2.29)
>109 15 (32.6) 19 (23.2) 8 (10.8) 8 (5.2)
OR (95% CI) 8.77 5.47 2.20 —
(3.42, 22.49) (2.27, 13.14) (0.79, 6.11)
*Age 45 years is the reference category. CI: confidence interval; HBV DNA, hepatitis B viral DNA; OR,
odds ratio
doi:10.1371/journal.pone.0121632.t002
Table 3. Association of age with high risk of MTCT (HBeAg-positive plus high viral load)*.
HBeAg-positive + HBV DNA levels,
copies/mL, n (%)
Age 24
years
Age 25–34
years
Age 35–44
years
Age 45
years
(n = 34) (n = 50) (n = 31) (n = 42)
>106 33 (97.1) 44 (88.0) 26 (83.9) 40 (95.2)
OR (95% CI) 1.65 0.37 0.26 —
(0.14, 19.01) (0.07, 1.92) (0.05, 1.44)
>107 33 (97.1) 42 (84.0) 25 (80.6) 33 (78.6)
OR (95% CI) 9.00 1.43 1.14 —
(1.08, 75.05) (0.50, 4.12) (0.36, 3.61)
>108 30 (88.2) 36 (72.0) 18 (58.1) 27 (64.3)
OR (95% CI) 4.17 1.43 0.77 —
(1.23, 14.10) (0.59, 3.45) (0.30, 1.99)
>109 15 (44.1) 19 (38.0) 7 (22.6) 6 (14.3)
OR (95% CI) 4.74 3.68 1.75 —
(1.58, 14.20) (1.31, 10.36) (0.52, 5.85)
*Age  45 years is the reference category. CI, confidence interval; HBV DNA, hepatitis B viral DNA;
HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; OR, odds ratio
doi:10.1371/journal.pone.0121632.t003
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those infected with genotypes A and D (Table 5). There was no obvious relationship between
genotype and viral load.
Discussion
This retrospective analysis demonstrates a strong relationship between patients’ age and
HBeAg status and viral load. Women of childbearing age ( 44 years) appeared significantly
more likely to be HBeAg positive and to have high levels of HBV DNA than women aged 45
Table 4. Association between ethnicity and age with viral load and HBeAg status
Asian Non-Asian Asian Non-Asian
44 years (n =
82)
45 years (n =
66)
44 years (n =
120)
45 years (n =
87)
(all ages) (n =
148)
(all ages) (n =
207)
HBeAg-positive, n (%) 60 (74.1) 25 (37.9) 55 (45.8) 17 (19.5) 85 (57.8) 72 (34.8)
OR (95% CI) 4.69 (2.32, 9.46) 3.48 (1.84, 6.61)
HBV DNA, copies/mL, n (%)
>106 60 (73.2) 50 (75.8) 86 (71.7) 49 (56.3) 110 (74.3) 135 (65.2)
OR (95% CI) 0.87 (0.41, 1.84) 1.96 (1.10, 3.51)
>107 54 (65.9) 34 (51.5) 72 (60.0) 32 (36.8) 88 (59.5) 104 (50.2)
OR (95% CI) 1.82 (0.93, 3.53) 2.58 (1.46, 4.55)
>108 40 (48.8) 19 (28.8) 53 (44.2) 20 (23.0) 59 (39.9) 73 (35.3)
OR (95% CI) 2.36 (1.19, 4.68) 2.65 (1.43, 4.91)
>109 14 (17.1) 1 (1.5) 28 (23.3) 7 (8.0) 15 (10.1) 35 (16.9)
OR (95% CI) 13.38 (1.71, 104.69) 3.48 (1.44, 8.39)
HBeAg-positive + HBV DNA, copies/
mL, n (%)
>106 50 (83.3) 25 (100.0) 53 (96.4) 15 (88.2) 75 (88.2) 68 (94.4)
OR (95% CI) nc 3.53 (0.46, 27.23)
>107 48 (80.0) 19 (76.0) 52 (94.5) 14 (82.4) 67 (78.8) 66 (91.1)
OR (95% CI) 1.26 (0.41, 3.85) 3.71 (0.67, 20.45)
>108 38 (63.3) 15 (60.0) 46 (83.6) 12 (70.6) 53 (62.4) 58 (80.6)
OR (95% CI) 1.15 (0.44, 3.00) 2.13 (0.60, 7.54)
>109 14 (23.3) 1 (4.0) 27 (49.1) 5 (29.4) 15 (17.6) 32 (44.4)
OR (95% CI) 7.30 (0.91, 58.92) 2.31 (0.72, 7.45)
CI, confidence interval; HBV DNA, hepatitis B viral DNA; HBeAg, hepatitis B e antigen; nc: not calculable; OR, odds ratio
doi:10.1371/journal.pone.0121632.t004
Table 5. Association between HBV genotype, HBeAg status and viral load.
GT A (n = 21) GT B (n = 21) GT C (n = 39) GT D (n = 82) GT A/D (n = 103) GT B/C (n = 60)
HBeAg positive, n (%) 10 (47.6) 13 (61.9) 29 (74.4) 27 (32.9) 37 (35.9) 42 (70.0)
HBV DNA, copies/mL, n (%)
> 106 19 (90.5) 20 (95.2) 34 (87.2) 68 (82.9) 87 (84.5) 54 (90.0)
> 107 15 (71.4) 16 (76.2) 27 (69.2) 53 (64.6) 68 (66.0) 43 (71.7)
> 108 10 (47.6) 12 (57.1) 21 (53.9) 33 (40.2) 43 (41.8) 33 (55.0)
> 109 3 (14.3) 4 (19.1) 6 (15.4) 20 (24.4) 23 (22.3) 10 (16.7)
GT, genotype; HBV DNA, hepatitis B viral DNA; HBeAg, hepatitis B e antigen
doi:10.1371/journal.pone.0121632.t005
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years and older. The highest proportion of women who were both HBeAg-positive and who
had high viral load, and who were therefore at greatest risk of MTCT, was seen in the24
years subgroup in our analysis. Rates of HBeAg positivity were higher in Asian versus non-
Asian patients, as would be expected from regional differences in HBV endemicity and the pre-
dominance of HBV genotypes B and C in Asian patients which were associated with higher
rates of HBeAg positivity in the current study. However, the most striking differences in
HBeAg-positive and high viral load prevalence were in relation to patients’ age.
Our finding that younger CHB female patients are more likely to be HBeAg positive and to
have high viral loads than older patients is consistent with other studies. In a systematic review,
worldwide prevalence of HBeAg positivity in HBsAg-positive women aged 20–39 years was
21–36%, depending on region, with HBeAg positivity rates being lower in those aged over 44
years, and decreasing with increasing age [16]. In the present analysis, 57.2% of women of
child-bearing age (44 years) were HBeAg positive compared with 27.5% of women aged45
years; in women aged34 years of age in our study, the rate of HBeAg positivity was even
higher (65.6%). This is higher than the rates estimated by Ott et al [16], and at the top end of
other published prevalence estimates for these age cohorts. For example, in a population-based
review, the median seroprevalence estimate of HBeAg in HBsAg-positive pregnant women was
14%, ranging from 0% in the Eastern Mediterranean region to 47.8% in some areas of the
Western Pacific Region [17]. However, Ott et al acknowledged that HBeAg positivity rates may
have been underestimated in their systematic review. Most studies on HBV seroprevalence in-
cluded in the review used HBsAg as a marker of infection, but few included information on
HBeAg, and several studies that reported HBeAg estimates had to be excluded as they were
conducted among high-risk populations or had methodological drawbacks [16]. In addition, it
is important to distinguish our study population, which was screened with the intention to par-
ticipate in clinical trials with strict eligibility criteria (e.g. abnormal ALT levels), from an unse-
lected seroprevalence community-based population that would include, for example, patients
with normal and abnormal ALT levels. Our study includes both those patients who fulfilled the
study inclusion criteria, and those who failed screening, thus lessening the impact of selection
criteria on the findings. Nevertheless the nature of our study population is likely to have con-
tributed to difference between our results and population-based studies.
The finding that younger CHB female patients are more likely to be HBeAg positive and to
have high viral loads than older patients is likely a reflection of the natural history of HBV in-
fection. The first immune tolerant phase of infection, characterized by HBeAg positivity and
very high levels of HBV DNA, can last from a few years to several decades. It is particularly
prolonged where HBV infection is acquired perinatally or in early childhood, the predominant
mode of infection in Asians. In such patients the immune tolerant phase can persist into early
adulthood, with a low rate of progression to subsequent phases of infection until later life.
Where infection arises due to horizontal transmission there is a more rapid progression to the
second phase of chronic infection, the HBeAg-positive immune active phase, which is associat-
ed with high or fluctuating HBV DNA levels. The timing of further progression to HBeAg-neg-
ative CHB, where HBV DNA levels are low, is variable. Younger women are therefore more
likely to be in the earlier phases of chronic infection, associated with HBeAg-positivity and
high HVB DNA levels. Of all risk factors, a high level of HBV DNA is considered the most im-
portant in MTCT [10], with MTCT occurring in cases of high viremia despite active and pas-
sive immunoprophylaxis [5–7,18,19]. Data show that risk of MTCT increases significantly in
line with increasing HBV DNA levels [7–18]. A number of studies have shown that MTCT is
predominantly seen in infants of HBeAg-positive, highly viremic mothers (6 log10 or7
log10 copies/mL) [5–7,18–21], whereas risk is negligible at low viral loads (HBV DNA of4
log10 copies/mL) [14]. In the present study, significantly more women aged44 years had high
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viral loads compared with those aged45 years, which was particularly marked at higher viral
load cut-off values (108 copies/mL and 109 copies/mL) and in patients in the youngest cohort
(24 years of age). This age group was also more likely to be HBeAg-positive with accompa-
nying high viral load and therefore at greatest risk of MTCT.
Treatment with lamivudine and with telbivudine during pregnancy has been shown to re-
duce serum HBV DNA and HBeAg levels, so decreasing the incidence of perinatal HBV trans-
mission [12–14,22]. TDF, a first-line treatment for patients with CHB and active disease which
has been assigned pregnancy category B by the FDA [23], may also be an appropriate option
for mothers who may need to continue antiviral therapy for active CHB following delivery.
This has been included in a suggested algorithm for risk assessment and prevention of MTCT
[10]. This algorithm suggests that, given the high risk of MTCT and high probability of immu-
noprophylaxis failure, women with high viral load (defined as>106 copies/mL) should receive
treatment with lamivudine, telbivudine or TDF (particularly in women with active CHB) in the
third trimester of pregnancy [10].
Asian patients in our analysis were predominantly infected with genotypes B and C. We ob-
served no substantial differences in the proportion of patients with high viral loads when strati-
fied by genotype, although infection with genotypes B and C was associated with a higher rate
of HBeAg positivity compared with genotypes A and D, with genotype C including the highest
proportion of HBeAg-positive women. Evidence regarding the importance of HBV genotype
in MTCT is evolving, and existing data are inconclusive. Some studies have failed to demon-
strate a link between HBV genotype and risk of MTCT [3,19]. However, higher HBeAg sero-
positivity rates have been demonstrated for genotype C carriers compared with genotype B
carriers [24] and genotype C has been associated with higher rates of infectivity [18,25]. The
higher rates of HBeAg positivity in women with genotype B and, especially genotype C infec-
tion, and associated increased risk of MTCT, emphasize the importance of MTCT prevention
in those parts of the world, such as Asia, where these genotypes are prevalent. In addition, as
perinatal infection is associated with an increased risk of chronic infection [1], the higher pro-
portion of HBeAg-positive women, and thus greater potential risk of MTCT, in genotype B
and C infection may have implications for the higher prevalence of HBV infection in Asian
countries compared with non-Asian countries where other genotypes predominate.
In summary, while it is known that the presence of HBeAg positivity together with a high
viral load constitutes a major risk for transmission of HBV from a chronically infected mother
to her child, prevalence data are scarce for this high-risk group. In female patients with CHB
screened for inclusion into two contemporary, large, randomized clinical HBV trials, women
of childbearing age with CHB had a greater likelihood of being HBeAg positive and having a
high HBV viral load than those aged 45 years or older. Younger women had the highest risk of
being HBeAg positive, and had the highest levels of HBV DNA, a combination which is associ-
ated with the greatest risk of MTCT. In addition, the proportion of HBeAg positivity was
higher in Asian women in our study compared with non-Asian patients, and in women in-
fected with genotypes B and C, the predominant genotypes in Asian populations. These find-
ings may help to explain higher rate of MTCT in highly endemic areas such as Asia, where age
at pregnancy tends to be lower and HBV genotype B and C are predominant.
Our findings have important implications for the management of HBV infection during
pregnancy. Asian women (who are predominantly infected with HBV genotypes B and C) may
have higher risk of MTCT than non-Asian women, while risk is highest in younger women. It
is clear that maternal serological and virological status should be established early in pregnan-
cy, taking into account age and genotype and that a risk-reducing strategy is implemented in
any patient who is HBeAg positive and has a high viral load.
(Study 102; NCT00117676, Study 103; NCT00116805)
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